JOHNSON JENNIFER M 4

What Happened

• Jennifer M. Johnson, a director of Thermo Fisher Scientific (TMO), was granted 66.02 deferred stock units on March 28, 2026. The units were valued at $473.36 each (66.02 × $473.36 ≈ $31,269). The filing lists this as an award/acquisition (derivative).

Key Details

• Transaction date: 2026-03-28; Form 4 filed: 2026-03-31.
• Transaction type/code: Award/Acquisition (A) — 66.02 deferred stock units.
• Unit price reported: $473.36 per unit; approximate aggregate value: $31,269.
• Footnote F1: Units convertible into common stock on a 1-for-1 basis.
• Footnote F2: Units were credited under the Issuer’s Deferred Compensation Plan for Directors (retainers deferred quarterly as common stock units); shares become distributable upon cessation of director service or a change of control.
• Shares owned after the transaction are not specified in the provided filing.
• Reporting-person remark: The filer is President/CEO and a director of Franklin Resources, Inc.; Franklin/Franklin Templeton subsidiaries manage accounts that may hold Thermo Fisher shares, and the reporting person disclaims beneficial ownership of those client holdings.

Context

• These are deferred stock units (derivative awards), not an open-market purchase or sale. Units will convert 1-for-1 into common shares and are typically paid out when the director leaves service or upon a change in control.
• Grants to directors are routine compensation and do not necessarily signal a personal buying or selling decision by the director.